Drugs Fut 2021, 46(2): 129
ISSN 0377-8282
Copyright 2021 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.2.3176879

TNP-2092. RNA polymerase (bacterial) inhibitor, DNA gyrase (bacterial) inhibitor, DNA topoisomerase IV (bacterial) inhibitor, Treatment of medical device-associated bacterial biofilm infections

Takare, R., Dasgupta, A., Chopra, S.

The unrelenting rise of drug-resistant infections including those caused by biofilm-forming bacterial pathogens negatively impacts morbidity and mortality worldwide and demands the urgent discovery and development of novel therapeutics. In this context, TNP-2092 is a multitargeting drug conjugate that is designed to exert antibacterial activity by inhibiting 3 essential bacterial targets, such as RNA polymerase, DNA gyrase and topoisomerase IV, and consists of rifampicin and a quinolizinone-derived pharmacophore (ABT-719). The hybrid demonstrated more potent activity compared with both parent drugs individually and has a low propensity for resistance development since it targets 3 essential bacterial enzymes. The U.S. Food and Drug Administration (FDA) has granted fast track and orphan drug designations to TNP-2092 powder for intravenous injection for the treatment of prosthetic joint infections. TNP-2092 has also received a qualified infectious disease product designation in the U.S.

Link to the article: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3176879&p_IsPs=N.‍

关于丹诺医药

丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。凭借自主开发的多靶点偶联分子技术，丹诺致力于为患者提供最佳治疗方案，以克服传统治疗的局限性并改善患者预后。截至2025年7月24日，丹诺已建立一条由七项创新资产组成的差异化管线，包括三项核心产品：即利福特尼唑 (TNP-2198)胶囊，是全球首个且唯一治疗幽门螺杆菌感染的新分子实体候选药物；利福喹酮(TNP-2092)注射剂，一款首创三靶点治疗植入体相关细菌感染的候选药物；及TNP-2092口服制剂，全球首个用于治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物。

如需更多信息，请访问：www.tennortherapeutics.com